Given the above conflicting results, a recent meta-analysis was performed, revealing that elevated IgE and blood eosinophil levels correlate with increased FeNO levels and that all these biomarkers of T2 inflammation may be useful for selecting asthma patients who may benefit more from omalizumab [164]. The gene discussed is IGHE; the disease is asthma.